Cancer Research Targets  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peng, X.
Right arrow Articles by Christov, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peng, X.
Right arrow Articles by Christov, K.
[Cancer Research 64, 8911-8918, December 15, 2004]
© 2004 American Association for Cancer Research


Regular Articles

A Novel RARß Isoform Directed by a Distinct Promoter P3 and Mediated by Retinoic Acid in Breast Cancer Cells

Xinjian Peng1, Takeshi Maruo3, Yanxia Cao2, Vasu Punj1, Rajeshwari Mehta1, Tapas K. Das Gupta1 and Konstantin Christov1

1 Department of Surgical Oncology, University of Illinois at Chicago, and 2 Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois; and 3 Department of Obstetrics and Gynecology, Kobe University School of Medicine, Kobe, Japan

Retinoids regulate gene transcription through activating retinoic acid receptors (RARs)/retinoic X receptors (RXRs). Of the three RAR receptors ({alpha}, ß, and {gamma}), RARß has been considered a tumor suppressor gene. Here, we identified a novel RARß isoform-RARß5 in breast epithelial cells, which could play a negative role in RARß signaling. Similar to RARß2, the first exon (59 bp) of RARß5 is RARß5 isoform specific, whereas the other exons are common to all of the RARß isoforms. The first exon of RARß5 does not contain any translation start codon, and therefore its protein translation begins at an internal methionine codon of RARß2, lacking the A, B, and part of C domain of RARß2. RARß5 protein was preferentially expressed in estrogen receptor-negative breast cancer cells and normal breast epithelial cells that are relatively resistant to retinoids, whereas estrogen receptor-positive cells that did not express detectable RARß5 protein were sensitive to retinoid treatment, suggesting that this isoform may affect the cellular response to retinoids. RARß5 isoform is unique among all of the RARs, because a corresponding isoform was not detectable for either RAR{alpha} or RAR{gamma}. RARß5 mRNA was variably expressed in normal and cancerous breast epithelial cells. Its transcription was under the control of a distinct promoter P3, which can be activated by all-trans-retinoic acid (atRA) and other RAR/RXR selective retinoids in MCF-7 and T47D breast cancer cells. We mapped the RARß5 promoter and found a region -302/-99 to be the target region of atRA. In conclusion, we identified and initially characterized RARß5 in normal, premalignant, and malignant breast epithelial cells. RARß5 may serve as a potential target of retinoids in prevention and therapy studies.




This article has been cited by other articles:


Home page
Cancer Res.Home page
E. Ohashi, T. Kogai, H. Kagechika, and G. A. Brent
Activation of the PI3 Kinase Pathway By Retinoic Acid Mediates Sodium/Iodide Symporter Induction and Iodide Transport in MCF-7 Breast Cancer Cells
Cancer Res., April 15, 2009; 69(8): 3443 - 3450.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Whyte, Y.-Y. Huang, K. Torres, and R. G. Mehta
Molecular Mechanisms of Resveratrol Action in Lung Cancer Cells Using Dual Protein and Microarray Analyses
Cancer Res., December 15, 2007; 67(24): 12007 - 12017.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
X. Peng, P. Jhaveri, E. A. Hussain-Hakimjee, and R. G. Mehta
Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1{alpha}-hydroxyvitamin D5
Carcinogenesis, May 1, 2007; 28(5): 1000 - 1007.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Huang, Z. D. Liang, T.-T. Wu, A. Hoque, H. Chen, Y. Jiang, H. Zhang, and X.-c. Xu
Tumor-Suppressive Effect of Retinoid Receptor-Induced Gene-1 (RRIG1) in Esophageal Cancer
Cancer Res., February 15, 2007; 67(4): 1589 - 1593.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Peng, R. Mehta, S. Wang, S. Chellappan, and R. G. Mehta
Prohibitin is a novel target gene of vitamin d involved in its antiproliferative action in breast cancer cells.
Cancer Res., July 15, 2006; 66(14): 7361 - 7369.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
W. J. Petty, N. Li, A. Biddle, R. Bounds, C. Nitkin, Y. Ma, K. H. Dragnev, S. J. Freemantle, and E. Dmitrovsky
A Novel Retinoic Acid Receptor {beta} Isoform and Retinoid Resistance in Lung Carcinogenesis
J Natl Cancer Inst, November 16, 2005; 97(22): 1645 - 1651.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.